EXOC6B

Across TCGA pan-cancer cohorts, EXOC6B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXOC6B data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher EXOC6B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOC6B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, SCLC, and ESCA are the cancer types where EXOC6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.133	0.805	<.001	42	view →
SCLC	OS	Median	II,III,IV	0.260	0.708	.005	15	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
SKCM	OS	Median	II,III,IV	0.327	0.744	.002	5	view →
UCEC	DFS	Median	II,III,IV	0.915	0.439	.039	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXOC6B–KIRC (OS)

Open the KIRC breakdown →